Mr. Chien Huang reports

TITAN REPORTS VOTING RESULTS FROM 2023 ANNUAL GENERAL AND SPECIAL MEETING

Titan Medical Inc. has released the voting results from its annual general and special meeting of shareholders (the AGM) held virtually via live audio webcast on Sept. 30, 2024. Shareholders voted in favour of all management resolutions proposed in Titan's management information circular dated Aug. 30, 2024.

Resolutions proposed and approved at the AGM include:

• Fixing the number of directors and election of directors of Titan for the ensuing year (director resolution);
• Appointing MNP LLP as auditor of Titan for the ensuing year and authorizing the directors to fix the remuneration of the auditor;
• Subject to the completion of the transaction (as defined herein), the change of name of Titan to Conavi Medical Inc.;
• The transactions contemplated by the amalgamation agreement dated March 17, 2024, among Conavi Medical Inc., Titan and 1000824255 Ontario Inc. (Subco), pursuant to which Conavi and Subco will amalgamate;
• Subject to completion of the transaction, Titan's new equity incentive plan representing 15 per cent of the outstanding securities of Titan immediately following completion of the transaction on a postclosing and fully diluted basis (incentive plan resolution);
• Subject to completion of the transaction, the consolidation of the shares on the basis of one postconsolidation share of Titan for each 25 preconsolidation shares of Titan (the consolidation resolution).

Certain of the directors nominated for election (as detailed below) did not receive a majority of votes in favour of their election. In accordance with titan's majority voting policy and the rules of the Toronto Stock Exchange, a further press release regarding the status of these directors will be provided at a later date.

A total of 60,264,549 of the 114,039,850 issued and outstanding shares of Titan or 52.85 per cent were voted at the AGM. The results of the vote were reported to the AGM by Computershare, which acted as scrutineer at the AGM and were as shown in the attached table.

About Titan Medical Inc.

Titan Medical, a medical technology company incorporated under the Business Corporations Act (Ontario) and headquartered in Toronto, Ont., has developed an expansive patent portfolio related to the enhancement of robotic-assisted surgery (RAS), including through a single access point, and is currently focused on evaluating new opportunities to further develop and license its intellectual property.

About Conavi Medical Inc.

Conavi Medical is a privately owned company focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid system is the first system to combine both IVUS and OCT to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid system has 510(k) clearance from the United States Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare.

We seek Safe Harbor.